Breast Cancer

  • Minetta C. Liu
  • Marc E. Lippman

Abstract

Breast cancer is the most frequently diagnosed malignancy in women and the second leading cause of cancer-related deaths in the United States, with approximately 183,000 new cases and 41,000 deaths expected in the year 2000 [1]. The incidence of advanced breast cancer and of death from breast cancer have remained fairly stable, but the number of in situ carcinomas and early-stage breast cancers has increased dramatically; as a result, the proportion of women diagnosed with invasive breast cancer who ultimately die of the disease has strikingly declined. This phenomenon most likely results from early detection through routine mammographic screening and advances in systemic therapy. In fact, retrospective analyses have clearly demonstrated an association between the stage of disease at diagnosis and prognosis with the following 5-year survival data: 97% for noninvasive disease; 78% for invasive disease confined to the breast and/or axilla; and 22% for metastatic disease [1].

Keywords

Anemia Oncol Diarrhea Methotrexate Bilirubin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Greenlee RT, Murray T, Bolden S, et al.: Cancer statistics, 2000. CA Cancer JClin 2000, 50: 7–33.CrossRefGoogle Scholar
  2. 2.
    Colditz GA, Willett WC, Hunter DJ, et al.: Family history, age, and risk of breast cancer. JAMA 1993, 270: 338–343.PubMedCrossRefGoogle Scholar
  3. 3.
    Ellisen LW, Haber DA: Hereditary breast cancer. Annu Rev Med 1998, 49: 425–436.PubMedCrossRefGoogle Scholar
  4. 4.
    Shapiro S: Periodic screening for breast cancer: the HIP Randomized Controlled Trial (Health Insurance Plan). JNatl Cancer Inst Monogr 1997, 22: 27–30.Google Scholar
  5. 5.
    Tabar L, Vitak B, Chen HH, et al.: The Swedish Two-County Trial twenty years later: updated mortality results with new insights for long-term follow-up. Radiol Clinic North Am 2000, 38: 625–651.CrossRefGoogle Scholar
  6. 6.
    Jardines L, Haffty BG, Theriault RL, et al.: Breast cancer overview: risk factors, screening, genetic testing, and prevention. In Cancer Management: A Multidisciplinary Approach. Edited by Pazdur R, Coia LR, Hoskins WJ, et al.: PRR: Melville; 2000: 135–157.Google Scholar
  7. 7.
    The uniform approach to breast fine-needle aspiration biopsy: NIH Consensus Development Conference. Am J Surg 1997, 174: 371–385.CrossRefGoogle Scholar
  8. 8.
    Breast. In American Joint Committee on Cancer’s AJCC Cancer Staging Manual. Edited by Fleming ID, Cooper JS, Henson DE, et al.: Philadelphia: Lippincott-Raven; 1997: 171–180.Google Scholar
  9. 9.
    Morrow M, Foster RS, Jr.: Staging of breast cancer: a new rationale for internal mammary node biopsy. Arch Surg 1981, 116: 748–751.PubMedCrossRefGoogle Scholar
  10. 10.
    Giuliano AE, Jones RC, Brennan M, et al.: Sentinel lymphadenectomy in breast cancer. J Clin Onco1 1997, 15: 2345–2350.Google Scholar
  11. 11.
    Isaacs C, Stearns V, Hayes DF: New prognostic factors for breast cancer recurrence. Submitted for publication.Google Scholar
  12. 12.
    Dupont WD, Page DL: Risk factors for breast cancer in women with proliferative breast disease. N EnglJ Med 1985, 312: 146–151.PubMedCrossRefGoogle Scholar
  13. 13.
    Dupont WD, Page DL, Parl FF, et al.: Long-term risk of breast cancer in women with fibroadenoma. N Engl J Med 1994, 331: 10–15.PubMedCrossRefGoogle Scholar
  14. 14.
    Page DL, Dupont WD, Rogers LW, et al.: Atypical hyperplastic lesions of the female breast: a long-term follow-up study. Cancer 1985, 55: 2698–2708.PubMedCrossRefGoogle Scholar
  15. 15.
    Rosen PP, Kosloff C, Lieberman PH, et al.: Lobular carcinoma in situ of the breast: detailed analysis of 99 patients with average follow-up of 24 years. Am J Surg Pathol 1978, 2: 225–251.PubMedCrossRefGoogle Scholar
  16. 16.
    Winchester DP, Jeske JM, Goldschmidt RA: The diagnosis and management of ductal carcinoma in situ of the breast. CA Cancer J Clin 2000, 50: 184–200.PubMedCrossRefGoogle Scholar
  17. 17.
    Simpson JF, Page DL: The role of pathology in premalignancy and as a guide for treatment and prognosis in breast cancer. Semin Oncol 1996, 23: 428–435.PubMedGoogle Scholar
  18. 18.
    Fisher B, Dignam J, Wolmark N, et al.: Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from the National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Onco1 1998, 16: 441–452.Google Scholar
  19. 19.
    Fisher B, Dignam J, Wolmark N, et al.: Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999, 353: 1993–2000.PubMedCrossRefGoogle Scholar
  20. 20.
    Silverstein MJ, Lagios MD, Craig PH, et al.: A prognostic index for ductal carcinoma in situ of the breast. Cancer 1996, 77: 2267–2274.PubMedCrossRefGoogle Scholar
  21. 21.
    Jordan VC, Lababidi MK, Langen-Fahey S: Suppression of mouse mammary tumorigenesis by long-term Tamoxifen therapy. JNatl Cancer Inst 1991, 83: 492–496.CrossRefGoogle Scholar
  22. 22.
    Early Breast Cancer Trialists’ Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998, 351: 1451–1467.CrossRefGoogle Scholar
  23. 23.
    Fisher B, Costantino JP, Wickerham DL, et al.: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. JNatl Cancerinst 1998, 90: 1371–1388.CrossRefGoogle Scholar
  24. 24.
    Powles T, Eeles R, Ashley S, et al.: Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomized chemoprevention trial. Lancet 1998, 352: 98–101.PubMedGoogle Scholar
  25. 25.
    Veronesi U, Maisonneuve P, Costa A, et al.: Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women (Italian Tamoxifen Prevention Study). Lancet 1998, 352: 93–97.PubMedGoogle Scholar
  26. 26.
    Early Breast Cancer Trialists’ Collaborative Group: Effects of radiotherapy and surgery in early breast cancer: an overview of the randomised trials. N Engl J Med 1995, 333: 1444–1455.CrossRefGoogle Scholar
  27. 27.
    Blichert-Toft M: Axillary surgery in breast cancer management: background, incidence and extent of nodal spread, extent of surgery and accurate axillary staging, surgical procedures. Acta Onco1 2000, 39: 269–275.Google Scholar
  28. 28.
    Ragaz J, Jackson SM, Le N, et al.: Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N EnglJ Med 1997, 337: 956–962.PubMedCrossRefGoogle Scholar
  29. 29.
    Overgaard M, Hansen PS, Overgaard J, et al.: Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. N EnglJ Med 1997, 337: 949–955.CrossRefGoogle Scholar
  30. 30.
    Overgaard M, Jensen MB, Overgaard J, et al.: Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant Tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomized trial. Lancet 1999, 353: 1641–1648.PubMedCrossRefGoogle Scholar
  31. 31.
    Early Breast Cancer Trialists’ Collaborative Group: Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: an overview of 61 randomised trials among 28,296 women. N Eng1 J Med 1988, 319: 1681–1692.CrossRefGoogle Scholar
  32. 32.
    Early Breast Cancer Trialists’ Collaborative Group: Systematic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992, 339: 1–15, 71–85.Google Scholar
  33. 33.
    Early Breast Cancer Trialists’ Collaborative Group: Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet 1996, 348: 1189–1196.CrossRefGoogle Scholar
  34. 34.
    Early Breast Cancer Trialists’ Collaborative Group: Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998, 352: 930–942.CrossRefGoogle Scholar
  35. 35.
    Fisher B, Dignam J, Mamounas EP, et al.: Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil. J Clin Oncol 1996, 14: 1982–1992.PubMedGoogle Scholar
  36. 36.
    Mansour EG, Gray R, Shatila AH, et al.: Survival advantage of adjuvant chemotherapy in high-risk node-negative breast cancer: ten-year analysis-an intergroup study. J Clin Onco1 1998, 16: 3486–3492.Google Scholar
  37. 37.
    Hutchins L, Green S, Ravdin P, et al.: CMF vs CAF with and without tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: first results of Intergroup Trial INT 0102. Proc Am Soc Clin Onco1 1998, 17: 1a.Google Scholar
  38. 38.
    Fisher B, Brown AM, Dimitrov NV, et al.: Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifennonresponsive tumors: Results from the National Surgical Adjuvant Breast and Bowel project B-15. J Clin Oncol 1990, 8: 1483–1496.PubMedGoogle Scholar
  39. 39.
    Fisher B, Anderson S, Wolmark N, et al.: Chemotherapy with or without Tamoxifen for patients with ER-negative breast cancer and negative nodes: results from NSABP B23. Proc Am Soc Clin Onco1 2000, 19: 72a.Google Scholar
  40. 40.
    Paik S, Bryant J, Park C, et al.: erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 1998, 90: 1361–1370.CrossRefGoogle Scholar
  41. 41.
    Seidman AD, Reichman BS, Crown JP, et al.: Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J Clin Onco1 1995, 13: 1152–1159.Google Scholar
  42. 42.
    Holmes FA, Walters RS, Theriault RL, et al.: Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991, 83: 1797–1805.CrossRefGoogle Scholar
  43. 43.
    Reichman BS, Seidman AD, Crown JD, et al.: Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1993, 11: 1943–1951.PubMedGoogle Scholar
  44. 44.
    Seidman AD, Tiersten A, Hudis C, et al.: Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Onco1 1995, 13: 2575–2581.Google Scholar
  45. 45.
    Henderson IC, Berry D, Demetri G, et al.: Improved disease free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (pts) with node-positive primary breast cancer (bc). Proc Am Soc Clin Onco1 1998, 17: 390a.Google Scholar
  46. 46.
    Fisher B, Anderson S, Wickerham DL, et al.: Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Onco1 1997, 15: 1858–1869.Google Scholar
  47. 47.
    Fisher B, Anderson S, DeCillis A, et al.: Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25. J Clin Onco1 1999, 17: 3374–3388.Google Scholar
  48. 48.
    Fisher B, Bryant J, Wolmark N, et al.: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Onco1 1998, 16: 2672–2685.Google Scholar
  49. 49.
    Rutqvist LE, Hatschek T, Ryden S, et al. (Swedish Breast Cancer Cooperative Group): Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Inst 1996, 88: 1543–1549.CrossRefGoogle Scholar
  50. 50.
    Current Trials Working Party of the Cancer Research Campaign Breast Cancer Trials Group: Preliminary results from the Cancer Research Campaign Trial evaluating tamoxifen duration in women aged fifty years or older with breast cancer. J Natl Cancer Inst 1996, 88: 1834–1839.CrossRefGoogle Scholar
  51. 51.
    Fisher B, Dignam J, Bryant J, et al.: Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 1996, 88: 1529–1542.CrossRefGoogle Scholar
  52. 52.
    Stewart HJ, Forrest AP, Everington D, et al.: Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer: the Scottish Cancer Trials Breast Group. Br J Cancer 1996, 74: 297–299.PubMedCrossRefGoogle Scholar
  53. 53.
    Taylor CW, Green S, Dalton WS, et al.: Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an Intergroup study. J Clin Onco1 1998, 16: 994–999.Google Scholar
  54. 54.
    Scottish Cancer Trials Breast Group and ICRF Breast Unit-Guy’s Hospital London: Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: the Scottish trial. Lancet 1993, 341: 1293–1298.Google Scholar
  55. 55.
    Kaufmann M: Luteinizing hormone-releasing hormone analogues in early breast cancer: updated status of ongoing clinical trials. Br J Cancer 1998, 78 (suppl 4): 9–11.PubMedCrossRefGoogle Scholar
  56. 56.
    Davidson N, O Neill A, Vukov A, et al.: Effect of chemohormonal therapy in premenopausal, node (+), receptor (+) breast cancer: an Eastern Cooperative Oncology Group phase III Intergroup trial (E5188, INT-0101). Proc Am Soc Clin Onco1 1999, 18: 67a.Google Scholar
  57. 57.
    Rutqvist LE: Zoladex and tamoxifen as adjuvant therapy in premenopausal breast cancer: a randomised trial by the Cancer Research Campaign (CRC) Breast Cancer Trials Group, the Stockholm Breast Cancer Study Group, the South-East Sweden Breast Cancer Group and the Gruppo Interdisciplinare Valutazione Interventi in Oncologia (GIVIO). Proc Am Soc Clin Onco1 1999, 18: 67a.Google Scholar
  58. 58.
    Recht A, Come SE, Henderson IC, et al.: The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. N Engl J Med 1996, 334: 1356–1361.PubMedCrossRefGoogle Scholar
  59. 59.
    Hortobagyi GN, Buzdar AU. Locally advanced breast cancer: a review including the MD Anderson experience. In High-Risk Breast Cancer. Edited by Rajaz J, Ariel IM: Berlin: Springer-Verlag; 1991: 382.CrossRefGoogle Scholar
  60. 60.
    McCready DR, Hortobagyi GN, Kau SW, et al.: The prognostic significance of lymph node metastases after preoperative chemotherapy for locally advanced breast cancer. Arch Surg 1989, 124: 21–25.PubMedCrossRefGoogle Scholar
  61. 61.
    Esteva FJ, Hortobagyi GN: Locally advanced breast cancer. Hematol Oncol Clin North Am 1999, 13: 457–472.PubMedCrossRefGoogle Scholar
  62. 62.
    Greenberg P, Hortobagyi G, Smith T, et al.: Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996, 14: 2197–2205.PubMedGoogle Scholar
  63. 63.
    Dickson RB, Lippman ME: Cancer of the breast. In Cancer: Principles and Practice of Oncology. Edited by DeVita VT, Hellman S, Rosenberg SA. Philadelphia: Lippincott-Raven Publishers; 1997: 1541–1616.Google Scholar
  64. 64.
    Ranson M, Carmichael J, O’Byrne K, et al.: Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol 1997, 15: 3185–3191.PubMedGoogle Scholar
  65. 65.
    Swain S, Whaley F, Gerber M, et al.: Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Onco1 1997, 15: 1318–1332.Google Scholar
  66. 66.
    Nabholtz JM, Senn HJ, Bezwoda WR, et al.: Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracyclinecontaining chemotherapy (304 study group). J Clin Onco1 1999, 17: 1413–1424.Google Scholar
  67. 67.
    Weber BL, Vogel C, Jones S, et al.: Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. J Clin Oncol 1995, 13: 2722–2730.PubMedGoogle Scholar
  68. 68.
    Carmichael J, Possinger K, Phillip P, et al.: Advanced breast cancer: a phase II trial with gemcitabine. J Clin Onco1 1995, 13: 2731–2736.Google Scholar
  69. 69.
    Garcia-Conde J, LLuch A, Perez-Manga G, et al.: Gemcitabine + doxorubicin in advanced breast cancer: final results from an early phase II study. Proc Am Soc Clin Onco1 1997, 16: 515a.Google Scholar
  70. 70.
    Neskovic-Konstantinovic ZB, Bosnjak SM, Radulovic SS, et al.: Daily oral etoposide in metastatic breast cancer. Anticancer Drugs 1996, 7: 543–547.PubMedCrossRefGoogle Scholar
  71. 71.
    Cameron DA, Gabra H, Leonard RC: Continuous 5-fluorouracil in the treatment of breast cancer. Br J Cancer 1994, 70: 120–124.CrossRefGoogle Scholar
  72. 72.
    Blum JL: Xeloda in the treatment of metastatic breast cancer. Oncology 1999, 57: 16–20.PubMedCrossRefGoogle Scholar
  73. 73.
    Klijn JGM, Blarney RW, Boccardo F, et al.: Combination LHRH—agonist plus tamoxifen treatment is superior to medical castration alone in premenopausal metastatic breast cancer. Breast Cancer Res Treat 1998, 50: 227.Google Scholar
  74. 74.
    Buzdar A, Jonat W, Howell A, et al.: Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. J Clin Onco1 1996, 14: 2000–2011.Google Scholar
  75. 75.
    Dombernowsky P, Smith I, Falkson G, et al.: Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Onco1 1998, 16: 453–461.Google Scholar
  76. 76.
    Kaufmann M, Bajetta E, Dirix LY, et al.: Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. (The Exemestane Study Group). J Clin Oncol 2000, 18: 1399–1411.PubMedGoogle Scholar
  77. 77.
    Hayes DF, Van Zyl JA, Hacking A, et al.: Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Onco1 1995, 13: 2556–2566.Google Scholar
  78. 78.
    Ettinger B, Black DM, Mitlak BH, et al.: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. (Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators). JAMA 1999, 282: 637–645.CrossRefGoogle Scholar
  79. 79.
    Howell A, Osborne CK, Morris C, et al.: ICI 182,780 (faslodex): development of a novel, “pure” antiestrogen. Cancer 2000, 89: 817–825.PubMedCrossRefGoogle Scholar
  80. 80.
    Slamon DJ, Clark GM, Wong SG, et al.: Human breast cancer: correlation of relapse and survival with amplification of HER-2/neu oncogene. Science 1987, 235: 177–182.PubMedCrossRefGoogle Scholar
  81. 81.
    Carlomagno C, Perrone F, Gallo C, et al.: c-erb-B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 1996, 14: 2702–2708.PubMedGoogle Scholar
  82. 82.
    Gusterson BA, Belber RD, Goldhirsch A, et al.: Prognostic importance of c-erb-B2 expression in breast cancer. J Clin Onco1 1992, 10: 1049–1056.Google Scholar
  83. 83.
    Muss HB, Thor AD, Berry DA, et al.: c-erb-B2 expression and response to adjuvant therapy in women with node-positive breast cancer. N EngIJ Med 1994, 330: 1260–1266.CrossRefGoogle Scholar
  84. 84.
    Gianni L: Future directions of paclitaxel-based therapy of breast cancer. Semin Oncol 1997, 24 (Suppl 17): 91–96.Google Scholar
  85. 85.
    Cobleigh MA, Vogel CL, Tripathy D, et al.: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2 overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Onco11999, 37: 2639–2648.Google Scholar
  86. 86.
    Slamon D, Leyland-Jones B, Shak S, et al.: Addition of Herceptin (humanized anti—Her2 antibody) to first line chemotherapy for Her2 overexpressing metastatic breast cancer (Her2+/MBC) markedly increases anticancer activity: a randomized, multinational controlled phase III trial. Proc Am Soc Clin Onco1 1998, 17: 98a.Google Scholar
  87. 87.
    Norton L, Slamon D, Leyland-Jones B, et al.: Overall survival (OS) advantage to simultaneous chemotherapy (CRx) plus the humanized anti—Her2 monoclonal antibody Herceptin (H) in Her2-overexpressing (Her2+) metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 1999, 18: 127a.Google Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Minetta C. Liu
  • Marc E. Lippman

There are no affiliations available

Personalised recommendations